BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 17198082)

  • 1. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells.
    Salem ML; Kadima AN; El-Naggar SA; Rubinstein MP; Chen Y; Gillanders WE; Cole DJ
    J Immunother; 2007 Jan; 30(1):40-53. PubMed ID: 17198082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity.
    Nair S; Boczkowski D; Fassnacht M; Pisetsky D; Gilboa E
    Cancer Res; 2007 Jan; 67(1):371-80. PubMed ID: 17210720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
    Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
    J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased CD4+CD25+Foxp3+ regulatory T cells in tolerance induced by portal venous injection.
    He F; Chen Z; Xu S; Cai M; Wu M; Li H; Chen X
    Surgery; 2009 Jun; 145(6):663-74. PubMed ID: 19486771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway.
    Haile LA; von Wasielewski R; Gamrekelashvili J; Krüger C; Bachmann O; Westendorf AM; Buer J; Liblau R; Manns MP; Korangy F; Greten TF
    Gastroenterology; 2008 Sep; 135(3):871-81, 881.e1-5. PubMed ID: 18674538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism.
    Yang T; Wall EM; Milne K; Theiss P; Watson P; Nelson BH
    Clin Cancer Res; 2007 Dec; 13(23):7172-80. PubMed ID: 18056198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of choroidal neovascularization by dendritic cell vaccination targeting VEGFR2.
    Mochimaru H; Nagai N; Hasegawa G; Kudo-Saito C; Yaguchi T; Usui Y; Kurihara T; Koto T; Satofuka S; Shinoda H; Ozawa Y; Tsubota K; Kawakami Y; Ishida S
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4795-801. PubMed ID: 17898306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant IL-15 does not enhance the efficacy of tumor cell lysate-pulsed dendritic cell vaccines for active immunotherapy of T cell lymphoma.
    Gatza E; Okada CY
    Cancer Immunol Immunother; 2006 Apr; 55(4):420-32. PubMed ID: 16025264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells.
    Zhang Q; Jang TL; Yang X; Park I; Meyer RE; Kundu S; Pins M; Javonovic B; Kuzel T; Kim SJ; Van Parijs L; Smith N; Wong L; Greenberg NM; Guo Y; Lee C
    Prostate; 2006 Feb; 66(3):235-47. PubMed ID: 16173028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmune-mediated intestinal inflammation-impact and regulation of antigen-specific CD8+ T cells.
    Westendorf AM; Fleissner D; Deppenmeier S; Gruber AD; Bruder D; Hansen W; Liblau R; Buer J
    Gastroenterology; 2006 Aug; 131(2):510-24. PubMed ID: 16890605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CD8 T cell response to vaccinia virus exhibits site-dependent heterogeneity of functional responses.
    Xiao Z; Curtsinger JM; Prlic M; Jameson SC; Mescher MF
    Int Immunol; 2007 Jun; 19(6):733-43. PubMed ID: 17545279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracellular CD154 expression reflects antigen-specific CD8+ t cells but shows less sensitivity than intracellular cytokine and MHC tetramer staining.
    Han YW; Aleyas AG; George JA; Yoon HA; Lee JH; Kim BS; Eo SK
    J Microbiol Biotechnol; 2007 Dec; 17(12):1955-64. PubMed ID: 18167442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of allergic airway inflammation by class I-restricted allergen presentation and CD8 T-cell infiltration.
    Wells JW; Cowled CJ; Giorgini A; Kemeny DM; Noble A
    J Allergy Clin Immunol; 2007 Jan; 119(1):226-34. PubMed ID: 17208606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DC-induced CD8(+) T-cell response is inhibited by MHC class II-dependent DX5(+)CD4(+) Treg.
    Han WG; Schuurhuis DH; Fu N; Camps M; van Duivenvoorde LM; Louis-Plence P; Franken KL; Huizinga TW; Melief CJ; Toes RE; Ossendorp F
    Eur J Immunol; 2009 Jul; 39(7):1765-73. PubMed ID: 19544486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses.
    Ruby CE; Redmond WL; Haley D; Weinberg AD
    Eur J Immunol; 2007 Jan; 37(1):157-66. PubMed ID: 17183611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4+CD25- T lymphocytes.
    Brillard E; Pallandre JR; Chalmers D; Ryffel B; Radlovic A; Seilles E; Rohrlich PS; Pivot X; Tiberghien P; Saas P; Borg C
    Exp Hematol; 2007 Mar; 35(3):416-25. PubMed ID: 17309822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of CD4+CD25+ regulatory T cells may underlie enhanced Th1 immunity caused by immunization with activated autologous T cells.
    Cao Q; Wang L; Du F; Sheng H; Zhang Y; Wu J; Shen B; Shen T; Zhang J; Li D; Li N
    Cell Res; 2007 Jul; 17(7):627-37. PubMed ID: 17563757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.
    Li L; Giannopoulos K; Reinhardt P; Tabarkiewicz J; Schmitt A; Greiner J; Rolinski J; Hus I; Dmoszynska A; Wiesneth M; Schmitt M
    Int J Oncol; 2006 Apr; 28(4):855-61. PubMed ID: 16525634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
    Jasani B; Navabi H; Adams M
    Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.